How this Weight Loss Injectable May Be the Key to Some Hearts

Wegovy (semaglutide) is transforming obesity treatment as the first drug approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) to reduce cardiovascular risks in people with excess weight or obesity. This breakthrough is backed by the SELECT trial, a large-scale study demonstrating Wegovy’s dual benefits for weight loss and heart health.

What Is Wegovy and How Is It Taken?

Wegovy, a GLP-1 receptor agonist, mimics a natural hormone to regulate appetite and blood sugar levels. It is taken as a once-weekly subcutaneous injection, with the dose gradually increased over 16 weeks to minimize possible side effects like nausea and diarrhea. Patients use a self-injecting pen designed for convenience.

The SELECT Trial: Evidence for Cardiovascular Benefits

In the SELECT trial, over 17,600 participants with cardiovascular disease and a BMI of 27 or higher (but no diabetes) were studied over five years. Wegovy reduced the risk of major adverse cardiovascular events (MACE)—including heart attacks, strokes, and cardiovascular deaths—by 20% compared to a placebo.

Why This Matters

Wegovy’s approval represents a shift in obesity treatment, addressing weight management and its critical link to cardiovascular disease. It offers new hope for individuals with obesity, providing not only significant weight loss but also a possible tangible reduction in life-threatening heart risks.

Did you know Rightangled offers a DNA heart test? Buy Heart DNA Test | Reveal Genetics – Rightangled

For Wegovy and other weight loss treatments available: Effective Weight Loss Solutions | Rightangled

References:

1. Novo Nordisk. "Semaglutide 2.4 mg reduced risk of cardiovascular events in people with obesity or overweight in SELECT trial."
2. European Society of Cardiology. "SELECT Trial Results." ESC Congress 2023.
3. Wilding J.P.H., et al. "Semaglutide 2.4 mg for Cardiovascular Risk Reduction in Patients with Obesity." The New England Journal of Medicine